Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, <i>13</i>, 1176

Abstract

We read, with great interest, the recently published article by Hopkins et al. [...]

Keywords

• n/a